SG Americas Securities LLC Purchases 39,089 Shares of Progyny, Inc. (NASDAQ:PGNY)

SG Americas Securities LLC grew its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 299.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 52,152 shares of the company's stock after purchasing an additional 39,089 shares during the period. SG Americas Securities LLC owned about 0.06% of Progyny worth $874,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Nordea Investment Management AB grew its holdings in shares of Progyny by 122.2% in the 1st quarter. Nordea Investment Management AB now owns 126,446 shares of the company's stock worth $4,891,000 after purchasing an additional 69,552 shares during the last quarter. Hsbc Holdings PLC grew its holdings in Progyny by 703.9% during the 2nd quarter. Hsbc Holdings PLC now owns 46,475 shares of the company's stock worth $1,328,000 after acquiring an additional 40,694 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Progyny by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 756,228 shares of the company's stock worth $21,636,000 after acquiring an additional 22,012 shares during the last quarter. Kestrel Investment Management Corp bought a new stake in Progyny during the 2nd quarter worth about $5,005,000. Finally, Farallon Capital Management LLC grew its holdings in Progyny by 120.8% during the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company's stock worth $37,436,000 after acquiring an additional 715,900 shares during the last quarter. Institutional investors own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. JMP Securities lowered shares of Progyny from an "outperform" rating to a "market perform" rating in a report on Thursday, September 19th. JPMorgan Chase & Co. decreased their price objective on shares of Progyny from $31.00 to $22.00 and set an "overweight" rating on the stock in a report on Thursday, September 19th. Canaccord Genuity Group downgraded shares of Progyny from a "buy" rating to a "hold" rating and cut their target price for the company from $37.00 to $24.00 in a research report on Wednesday, August 7th. Leerink Partners cut their target price on shares of Progyny from $25.00 to $21.00 and set a "market perform" rating on the stock in a research report on Thursday, September 19th. Finally, Truist Financial cut their target price on shares of Progyny from $33.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, September 19th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $27.73.

Insiders Place Their Bets

In other Progyny news, President Michael E. Sturmer sold 9,030 shares of the firm's stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total transaction of $270,900.00. Following the sale, the president now directly owns 362,583 shares in the company, valued at approximately $10,877,490. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 12.30% of the company's stock.

Progyny Trading Down 2.1 %

Shares of NASDAQ:PGNY traded down $0.35 during mid-day trading on Friday, reaching $16.10. The stock had a trading volume of 1,117,637 shares, compared to its average volume of 1,348,331. The firm has a market cap of $1.45 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.55 and a beta of 1.43. The firm has a 50 day simple moving average of $20.51 and a two-hundred day simple moving average of $26.56. Progyny, Inc. has a twelve month low of $13.93 and a twelve month high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, hitting the consensus estimate of $0.17. The firm had revenue of $304.09 million for the quarter, compared to the consensus estimate of $305.32 million. Progyny had a net margin of 5.54% and a return on equity of 11.97%. The business's quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the company posted $0.15 EPS. On average, equities analysts anticipate that Progyny, Inc. will post 0.64 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.